Merck KGaA (FRA:MRK) has been assigned a €100.00 ($116.28) price objective by investment analysts at Goldman Sachs Group, Inc. (The) in a note issued to investors on Monday. The firm currently has a “neutral” rating on the healthcare company’s stock. Goldman Sachs Group, Inc. (The)’s target price suggests a potential upside of 11.36% from the stock’s previous close.
Other research analysts have also issued research reports about the company. Deutsche Bank AG set a €106.00 ($123.26) price objective on Merck KGaA and gave the company a “neutral” rating in a report on Friday, August 4th. J P Morgan Chase & Co restated a “neutral” rating on shares of Merck KGaA in a research note on Friday, August 4th. DZ Bank AG restated a “neutral” rating on shares of Merck KGaA in a research note on Tuesday, November 14th. S&P Global set a €110.00 ($127.91) target price on Merck KGaA and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Commerzbank Ag set a €109.00 ($126.74) target price on Merck KGaA and gave the company a “neutral” rating in a research note on Thursday, August 3rd. Eleven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of €108.76 ($126.47).
Merck KGaA (FRA:MRK) opened at €89.80 ($104.42) on Monday. Merck KGaA has a 52-week low of €89.21 ($103.73) and a 52-week high of €115.00 ($133.72).
COPYRIGHT VIOLATION NOTICE: “Goldman Sachs Group, Inc. (The) Analysts Give Merck KGaA (MRK) a €100.00 Price Target” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/11/20/goldman-sachs-group-inc-the-analysts-give-merck-kgaa-mrk-a-100-00-price-target.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.